Report cover image

Carcinoid Syndrome Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035

Publisher BIS Research
Published Dec 08, 2025
SKU # BIS20636246

Description

Market Overview

The global carcinoid syndrome market is driven by the increasing prevalence of neuroendocrine tumors, which often lead to carcinoid syndrome. This syndrome is characterized by symptoms such as diarrhea, flushing, and wheezing, caused by hormone secretion from carcinoid tumors. The market is primarily driven by the availability of FDA-approved treatments to manage symptoms. Increasing awareness, improved diagnostics, and the growing number of diagnosed carcinoid syndrome cases are contributing to market growth. However, challenges such as high treatment costs and limited treatment options for advanced cases may hinder market expansion.

Impact

Increasing demand for carcinoid syndrome therapies is anticipated to support the growth of the global carcinoid syndrome market during the forecast period 2025-2035.
The global carcinoid syndrome market is expected to grow at a significant rate due to advancements in treatment, the development of innovative therapies, and increasing awareness among patients and healthcare providers.

The North America market holds the largest share in the global carcinoid syndrome market, driven by advanced healthcare infrastructure, widespread awareness of neuroendocrine tumors (NETs), and the availability of FDA-approved treatments. The U.S. leads in both diagnosis and treatment, with innovative therapies such as somatostatin analogs and Xermelo widely accessible.

Demand – Drivers and Limitations

The following are the drivers for the global carcinoid syndrome market:

Rising Prevalence of Neuroendocrine Tumors (NETs): The increasing incidence of neuroendocrine tumors, which often lead to carcinoid syndrome, is a significant driver for the market. Improved diagnostic capabilities and greater awareness are contributing to higher detection rates of carcinoid syndrome.
Advancements in Treatment Options: The availability of innovative FDA-approved therapies is expanding treatment options, improving patient outcomes, and driving market growth.
Increasing Awareness and Early Diagnosis: Enhanced awareness of carcinoid syndrome among healthcare professionals and patients has led to earlier diagnosis and more effective management of symptoms, boosting the demand for treatments.

The global Carcinoid Syndrome market is expected to face some limitations too, due to the following challenges:

High Treatment Costs: The cost of advanced therapies such as PRRT and somatostatin analogs can be prohibitive, particularly in low- and middle-income countries, limiting access to treatment.

Key Market Players and Competition Synopsis

The global carcinoid syndrome market is dominated by several key players focused on innovative treatments for managing symptoms associated with carcinoid syndrome. The competition in this market is primarily driven by ongoing innovation, with an emphasis on targeted therapies, regulatory approvals, and improved patient outcomes in managing the complex symptoms of carcinoid syndrome.

Some of the prominent names established in the global carcinoid syndrome market are:

Novartis AG
Ipsen
Lexicon Pharmaceuticals
Crinetics

*PDF email from publisher allows for 1-3 users, with permission to print*

Please Note: It will take 7-10 business days to complete the report upon order confirmation.

Table of Contents

Executive Summary
Scope of Study
Research Methodology
1. Global Carcinoid Syndrome Market: Industry Outlook
1.1 Market Overview
1.2 Clinical Trials
1.3 Regulatory Landscape / Compliance
1.4 Key Trends
1.5 Market Dynamics
1.5.1 Impact Analysis
1.5.2 Market Drivers
1.5.3 Market Restraints
1.5.4 Market Opportunities
2. Global Carcinoid Syndrome Market (By Region), $Million, 2023-2035
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Sizing and Forecast
2.1.2.1 North America Carcinoid Syndrome Market, by Country
2.1.2.1.1 U.S.
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Sizing and Forecast
2.2.2.1 Europe Carcinoid Syndrome Market, by Country
2.2.2.1.1 U.K.
2.2.2.1.2 Germany
2.2.2.1.3 France
2.2.2.1.4 Italy
2.2.2.1.5 Spain
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Sizing and Forecast
2.3.2.1 Asia-Pacific Carcinoid Syndrome Market, by Country
2.3.2.1.1 Japan
3. Global Carcinoid Syndrome Market - Competitive Landscape and Company Profiles
3.1 Key Developments and Strategies
3.1.1 Funding Activities
3.1.2 Mergers and Acquisitions
3.1.3 Regulatory Approvals
3.1.4 Partnerships, Collaborations and Business Expansions
3.2 Company Profiles
3.2.1 Novartis AG
3.2.1.1 Company Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers/End Users
3.2.1.4 Analyst View
3.2.2 Ipsen Pharma
3.2.2.1 Company Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers/End Users
3.2.2.4 Analyst View
3.2.3 Lexicon Pharmaceuticals
3.2.3.1 Company Overview
3.2.3.2 Product Portfolio
3.2.3.3 Target Customers/End Users
3.2.3.4 Analyst View
3.2.4 Crinetics
3.2.4.1 Company Overview
3.2.4.2 Product Portfolio
3.2.4.3 Target Customers/End Users
3.2.4.4 Analyst View
3.2.5 Others
4. Research Methodology
List of Figures
Figure: Carcinoid Syndrome Market (by Scenario), $Million, 2024, 2030, and 2035
Figure: Global Carcinoid Syndrome Market, 2024 and 2035
Figure: Global Carcinoid Syndrome Market Key Trends, Impact Analysis, 2023-2035
Figure: North America Carcinoid Syndrome Market, $Million, 2023-2035
Figure: Europe Carcinoid Syndrome Market, $Million, 2023-2035
Figure: Asia-Pacific Carcinoid Syndrome Market, $Million, 2023-2035
List of Tables
Table: Market Snapshot
Table: Market Dynamics
Table: Global Carcinoid Syndrome Market (by Region), $Million, 2023-2035

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us